Apolipoprotein E polypeptides and their use
Disclosed herein are several apoplipoprotein E (ApoE) polypeptides, and nucleic acids encoding these polypeptides, that can be used to treat or prevent a hepatitis infection in a subject, such as a hepatitis C virus infection. These ApoE polypeptides can inhibit the entry of hepatitis C virus into cells, and inhibit viral replication. Nucleic acids encoding these polypeptides are also disclosed, as well as methods.
1. A non-naturally occurring isolated polypeptide consisting of the amino acid sequence of SEQ ID NO: 8 or the amino acid sequence of SEQ ID NO: 9.
2. The non-naturally occurring isolated polypeptide of claim 1 , consisting of the amino acid sequence of SEQ ID NO: 8.
3. The non-naturally occurring isolated polypeptide of claim 1 , consisting of the amino acid sequence of SEQ ID NO: 9.
4. A dimer comprising two identical polypeptides, each with an N-terminus and a C-terminus, wherein each of the two polypeptides consists of the amino acid sequence of SEQ ID NO: 8 or the amino acid sequence of SEQ ID NO: 9, wherein the dimer inhibits the entry of hepatitis C virus into a host cell.
5. A composition comprising an effective amount of an isolated polypeptide consisting of the amino acid sequence of SEQ ID NO: 8 or the amino acid sequence of SEQ ID NO:9 or a dimer comprising two identical polypeptides, wherein each of the two polypeptides consists of the amino acid sequence of SEQ ID NO:8 or the amino acid sequence of SEQ ID NO:9, and a pharmaceutically acceptable carrier.
6. The dimer of claim 4 , wherein each of the polypeptides consists of the amino acid sequence of SEQ ID NO: 8.
7. The dimer of claim 4 , wherein each of the polypeptides consists of the amino acid sequence of SEQ ID NO: 9.
8. A pharmaceutical composition comprising an effective amount of the dimer of claim 4 , and a pharmaceutically acceptable carrier.
9. A pharmaceutical composition comprising an effective amount of the dimer of claim 7 , and a pharmaceutically acceptable carrier.
10. A pharmaceutical composition comprising an effective amount of the dimer of claim 6 , and a pharmaceutically acceptable carrier.
11. A method of inhibiting the entry of hepatitis C virus into a host cell, comprising, contacting the host cell with an effective amount of the polypeptide or dimer of claim 5 , thereby inhibiting entry of the hepatitis C virus into the cell.
12. The method of claim 11 , wherein the host cell is in vitro.
13. The method of claim 11 , wherein the host cell is in vivo.
14. The method of claim 11 , wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 8.
15. The method of claim 11 , wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 9.